Slanmhor Pharmaceutical, Inc. is a Canadian corporation with headquarters in Halifax, Nova Scotia. Slanmhor specializes in the manufacture and supply chain management of omega-3 based Active Pharmaceutical Ingredients. Slanmhor is a wholly-owned subsidiary of Clearwater Fine Foods, Inc., a Canadian based investment holding company with principal holdings that also include seafood harvesting, processing and telecommunications.
This press release contains forward-looking statements, including statements about the manufacturing capacity and qualification of Vascepa suppliers and planned regulatory approvals and timing related thereto. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with reliance on third parties, manufacturing capabilities, supply of pharmaceutical product and related regulatory approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Amarin contact information: Stephen D. Schultz Investor Relations and Corporate Communications Amarin Corporation In U.S.: +1 (908) 719-1315 firstname.lastname@example.org